Romidepsin and afatinib abrogate JAK-STAT signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma

Cutaneous T-cell lymphomas (CTCL) are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T cells. A distinctive clinical feature of CTCL is their sensitivity to treatment with histone deacetylase (HDAC) inhibitors. However, responses to HDAC inhibitor therapy are universally transient and non-curative, highlighting the need for effective and durable drug combinations. Here we demonstrate that the combination of romidepsin, a selective class I HDAC inhibitor, with afatinib, an epidermal growth factor receptor (EGFR) family inhibitor, induces strongly synergistic antitumor effects in CTCL models in vitro and in vivo via abrogation of JAK-STAT signalling.

Source: Journal of Investigative Dermatology - January 12, 2024 Category: Dermatology Authors: Bobby B. Shih, Cindy Ma, Jose R. Cortes, Clara Reglero, Hannah Miller, S. Aidan Quinn, Robert Albero, Anouchka P. Laurent, Adam Mackey, Adolfo A. Ferrando, Larisa Geskin, Teresa Palomero Tags: Original Article Source Type: research